Best Genomics Companies in Ontario, Canada
The 101 best Genomics companies in Ontario, Canada in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Geneseeq.
Our analysis of 50 Genomics companies
$7.8b in tracked funding; 84% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Genomics companies in Ontario
| # | Company | Disclosed funding | Last round | Stage | Employees | Founder | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Geneseeq Providing personalised cancer treatment solutions based on patients genomic profile 55Talent top 28%Funding top 31%Moat top 40%Market bottom 49% All 5 signals ▾Talenttop 28% Fundingtop 31% Moattop 40% Marketbottom 49% Globalbottom 45% Talent: 4 named leaders on record · 4 C-suite/founder profiles curated Funding: Raised $128M across 3 rounds · 3 rounds over 12 yrs (0.2/yr) rank vs industry peers · Fliar Intelligence Index 55/100 | $128M | 77 mo ago | Series D | — | Xiaonan Wang Co-Founder & CTO | — | — |
| 2 | Xagenic Provider of point-of-care molecular diagnostics for infectious diseases | $59M | 131 mo ago | Series C | 45 | — | 50 patents Electrochemical biosensor platforms and precision current‑mode DACs for point‑of‑care diagnostics | — |
| 3 | StageZero Life Sciences Developer of liquid biopsy test for the detection of cancer and multiple diseases | $59M | 46 mo ago | Public | 40 | James Tripp CEO | — | — |
| 4 | Qvella Developer of a platform aimed to provide a more accurate and faster diagnosis of bacteria identification | $40M | 102 mo ago | Deadpooled | 101 | — | 85 patents Rapid microbial diagnostics: cell separation, microcolony classification, and antibiotic susceptibility testing. | — |
| 5 | iVexSol Developer of a platform for the production of vectors | $39M | 40 mo ago | Series A | 34 | Rodney Rietze Co-Founder & CEO | — | — |
| 6 | Performance Plants Developer of technologies improving crop yields through stress tolerance and efficiency | $36M | 207 mo ago | Series B | 14 | Yafan Huang Chief Executive Officer | 106 patents Genetically engineered crops with enhanced water-use efficiency and stress tolerance. | — |
| 7 | Fio Point-of-care digital diagnostic integrated with cloud information services for infectious diseases | $11M | 114 mo ago | Series B | 40 | Michael Greenberg Chairman and Chief Executive Officer | 190 patents Point‑of‑care rapid immunoassay diagnostics with biomarker analytics and cloud data integration | — |
| 8 | Rapid Novor Provider of antibody sequencing & discovery services | $5M | 70 mo ago | Series A | 70 | — | 23 patents Antibody sequencing, chain pairing, and immunoglobulin light‑chain dimer detection/quantification | 1 launch |
| 9 | DoseBiome Provider of prebiotic and probiotic products | $4M | — | Deadpooled | 9 | Ted Jin Founder & CEO | — | — |
| 10 | Esphera SynBio Developer of cancer and immunoregulatory treatments using synthetic biology 45Talent top 28%Funding top 45%Global bottom 33% All 3 signals ▾Talenttop 28% Fundingtop 45% Globalbottom 33% Talent: 3 named leaders on record · 3 C-suite/founder profiles curated Funding: Raised $2.4M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 45/100 | $2M | 1 mo ago | Seed | — | John Bell Co-Founder | — | — |
| 11 | Mitomics Molecular diagnostics based on mitochnodrial genome | $2M | 152 mo ago | Acqui-Hired | — | Christopher Mitton CEO | 57 patents Mitochondrial DNA deletion/ fusion biomarkers for cancer and UV‑damage diagnostics | — |
| 12 | Ranomics Database of rare genetic variants | $1M | 117 mo ago | Seed | 6 | — | 7 patents High-throughput multisite saturation mutagenesis and splice‑junction variant analysis for gene engineering | — |
| 13 | Spartan Bioscience DNA testing systems | $284K | 135 mo ago | Series A | 54 | — | 57 patents Rapid nucleic acid sample preparation, amplification, and detection technologies for diagnostics | — |
| 14 | Spindle Biotech Providers of tools for gene editing research | $250K | 84 mo ago | Acqui-Hired | 2 | Aaron Chung CEO | 6 patents In vitro RNA synthesis reagents and methods for producing synthetic RNA molecules | — |
| 15 | Amino Provider of lab equipment for bacterial transformations and culture growth | $250K | 128 mo ago | Seed | 6 | — | — | — |
| 16 | Advanced Chemistry Development Labs Cheminformatics system | $245K | 61 mo ago | Acquired | 183 | — | — | 1 launch |
Top 12 Genomics companies in Ontario
#1
Seed · Ottawa, Ontario · founded 2022$2.4Mraised▾
Developer of cancer and immunoregulatory treatments using synthetic biology. The platform focuses on altering tumor-derived exosomes in vivo such that they become immunostimulatory, antigen-bearing TME and patient-specific cancer vaccines.
- May 2026Seed$365.5K
- Jan 2025Seed$2M
- Dec 2024Grant (prize money)—
#2
Public · Richmond Hill, Ontario · founded 1997 · 40 employees$58.8Mraised▾
StaDeveloper of liquid biopsy test for the detection of cancer and multiple diseases. The company has developed blood-based biomarker tests for the early identification of colorectal cancer known as ColonSentry which uses proprietary Sentinel principle technology. Also, it develops Aristotle mRNA-based, multi-cancer panel for screening multiple cancers.
- Aug 2022Post IPO$177K
- Mar 2022Post IPO$1.5M
- Nov 2021Post IPO$3.3M
- Dec 2020Post IPO$198.3K
#3
Series A · Toronto, Ontario · founded 2018 · 34 employees$39Mraised▾
iVexSol is a manufacturer and developer of the vector. It offers its flagship intelligent transformative platform for developing lentiviral vector cell lines.
- Jan 2023Series A$23.8M
- Dec 2020Series A$13M
- Aug 2020Seed$250K
- Sep 2019Seed$2M
#4
Series D · Toronto, Ontario · founded 2012$128.4Mraised▾
Geneseeq is a health solutions company that specializes in personalized cancer care and provides treatment solutions based on the comprehensive analyses of patients’ genomic profile (RNA) using NGS techniques primarily has developed customized RNA extraction protocols for all kinds of patient sample materials, including surgical sections, core needle biopsies, FFPE samples, and ultra-low input samples.
- Dec 2019Series D$114.4M
- Jul 2017Series C—
- Jun 2016Series B$9.4M
- Aug 2014Series A$4.7M
#5
Series C · Toronto, Ontario · founded 2010 · 45 employees$59.1Mraised▾
Xagenic is developing a point-of-care platform for decentralized, rapid molecular diagnostic testing. The Xagenic X1 technology platform permits the rapid, enzyme-free detection of nucleic acids from clinical samples with automated proprietary Xagenic AuRA cartridges. The procedure involves the patient's clinical specimen to be introduced into the cartridge using a proprietary specimen collection kit and tube that snaps into the cartridge. Then, after the insertion of the cartridge into the Xagenic X1 instrument, all processes are fully automated. It is also developing assays for infectious diseases to be used with their platform.
- Jul 2015Series C$11.8M
- Jul 2014Series B$25.5M
- Dec 2013Series A$9.6M
- Jan 2012Series A$10M
#6
Series B · Kingston, Ontario · founded 1995 · 14 employees$35.6Mraised▾
Developer of technologies improving crop yields through stress tolerance and efficiency. The company provides tools for seed companies to help their customers. Its technologies deliver native plant traits that maximize crop performance and productivity. The company’s technology aims to ensure global food supplies meet rising demands.
- Mar 2009Grant (prize money)$4.3M
- Jul 2008Series B$12.9M
- Jun 2006Series B$10.7M
- Mar 2005Series A$1.2M
#7
Deadpooled · Richmond Hill, Ontario · founded 2009 · 101 employees$39.7Mraised▾
Developer of a platform aimed to provide a more accurate and faster diagnosis of bacteria identification. The company offers sample preparation and detection technologies to clinical microbiology; Qvella's Field Activated Sample Treatment (FAST) technology utilizes a novel electrical lysing and sample treatment technique enabling rapid detection of infectious agents in a direct blood sample.
- Dec 2017Series B$19.7M
- Jun 2017Series A—
- Oct 2015Series A$20M
#8
Series B · Toronto, Ontario · founded 2006 · 40 employees$10.7Mraised▾
Point-of-care digital diagnostic integrated with cloud information services for infectious diseases. The company has developed a portable point-of-care device capable of molecular diagnosis of multiple infectious diseases from a small biological sample. Their product, Fionet, provides a point-of-care diagnosis for infectious disease. It works with mobile devices which automatically transmits primary data to a central web portal.
- Dec 2016Series B$8.3M
- Oct 2015Series A$75.7K
- Nov 2014Series A$100K
- Oct 2014Series A$704.8K
#9
Series A · Kitchener, Ontario · founded 2015 · 70 employees$5Mraised▾
Provider of antibody sequencing & discovery services. These analytical technologies are to be applied to early-stage drug research and development in the biopharmaceutical sector. The company is built around the research of Dr. Ma, a bioinformatician who developed the de novo sequencing tool, Novor. It is claimed that Novor achieved a speed of 300 spectra per second with a MacBook Pro laptop computer, with accuracy better than other available tools. This speed of the analytical software may enable applications that were not possible in the past. Services offered include Antibody Protein Sequencing and Expression.
- Jul 2020Series A$5M
- 2018Seed—
#10
Seed · Hamilton, Ontario · founded 2018$25Kraised▾
Platform offering at home biological age test toolkit. It provides a personalized insights and recommendations for living a longer, healthier life by combining epigenetic testing. It allows users to receive the results through the mobile app, which provides personalized insights and recommendations based on the biomarker data. It allows individuals to take a proactive approach to managing the health and aging process.
- Jan 2025Seed$25K
- 2020Seed—
#11
Deadpooled · Toronto, Ontario · founded 2016 · 9 employees$4.3Mraised▾
DoseBiome is focused on oral microbiome research that improves the microbial ecosystem in the mouth by preventing diseases such as dental caries and periodontal conditions. The company is developing pre/probiotic consumer products that selectively reduce bad bacteria while promoting healthy populations of the good.
- Series A$4.3M
#12
Acqui-Hired · Thunder Bay, Ontario · founded 2010$2.2Mraised▾
Mitomics, formerly Genesis Genomics, developed molecular diagnostics based on the mitochondrial genome. The company was developing assays for oncology, including skin, breast, prostrate and lung cancers. Its flagship product; Prostate Core Mitomic Test aimed to identify men at high risk of having a prostate tumor that was missed by the prostate biopsy procedure, supposedly without the need for further invasive biopsy procedures. Mitomics was acquired by MDNA Life Sciences in Nov 2014.
- Sep 2013Series A$2.1M
- Mar 2013Seed$100K
- Sep 2011Seed$51.1K
- Jun 2011Conventional Debt$25.6K
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Genomics coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Bioinformatics in Ontario is moving
A read on the academic research around Bioinformatics in Ontario — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 59 papers.
Ontario Institute for Cancer Research and allied institutions lead genomics and cancer diagnostics research across 59 papers, with cautiously optimistic momentum (mean stance 0.45) accelerating markedly post-2020.
- Ontario Institute for Cancer Research29
- Children\'s Hospital of Eastern Ontario9
- Public Health Ontario9
- Ontario Brain Institute5
- Ontario Genomics4
- Genome1→3
- Cancer1→3
- Disease2
- Identification (biology)2
- Computational biology2
- Cancer2
- Mutation2
- Genome2
- Transcriptome2
- Phenotype2
- Polygenic risk score1
- MAMMOGRAPHIC DENSITY1
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.